|Bid||59.81 x 50000|
|Ask||59.92 x 50000|
|Day's Range||58.71 - 60.00|
|52 Week Range||53.00 - 68.59|
|Beta (3Y Monthly)||0.61|
|PE Ratio (TTM)||13.14|
|Forward Dividend & Yield||2.25 (4.02%)|
|1y Target Est||N/A|
Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.
Wells Fargo & Co. (WFC), United Parcel Service Inc. (UPS), Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Company (BMY) have declined to their three-year lows. The prices of Wells Fargo & Co. (WFC) shares have declined to $44.37 on May 31, which is only 3.0% above the 3-year low of $43.02. Wells Fargo & Co. is an American international banking and financial services holding company.
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Growth driversSince the second quarter of 2016, Gilead Sciences (GILD) has been reporting major YoY (year-over-year) revenue declines, mainly due to its lower HCV
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)MS revenue performance in the first quarterIn the first quarter, Biogen (BIIB) reported MS (multiple sclerosis) franchise revenue of ~$2.1 billion including
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)NASH failed trialsOn February 11, Gilead Sciences (GILD) issued a press release announcing the top line results from its Phase 3 STELLAR-4 study evaluating the
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Failed programOn March 21, Biogen (BIIB) issued a press release announcing the discontinuation of its Phase 3 trials ENGAGE and EMERGE evaluating its leading
downgraded the biopharmaceutical company to sell from neutral. Analyst Terrence Flynn also lowered his price target to $60 from $70 for the Foster City, California-based company. Longer term, Flynn projected that Gilead Sciences' treatment Biktarvy can only protect about half of the company's $16 billion HIV franchise from generic competition.
Shares of the biotech firm Gilead Sciences Inc. were trading down, after an analyst at Goldman Sachs downgraded the stock and slashed his price target.
Gilead's topline is likely to decelerate in the near term, as the Truvada/Atripla loss of exclusivity in September 2020 represents a $3-billion headwind, Flynn said in a Tuesday downgrade note. In the long-term, the analyst expects Biktarvy to protect only half of the company's $16-billion HIV franchise from generic competition.
O’Day faced questioning at a Thursday hearing over the high price of Truvada, a medicine approved to treat HIV and prevent infection. Activists claim that the price prevents at-risk people from accessing the drug and has helped keep infection rates high. Truvada’s annual list price has nearly tripled in the U.S. to more than $20,000 over the past 15 years. News broke in April that the government is reviewing patents on Truvada’s preventative use that could entitle taxpayers to millions in royalties.
Pharmaceutical giant Gilead Sciences engaged in a "long-running scheme" to block generic competition of its combination drug "cocktails" to treat HIV. The complaint, filed in the U.S. District Court in San Francisco, names drugmakers Bristol-Myers Squibb and Johnson & Johnson subsidiary Janssen Pharmaceuticals as co-defendants. The plaintiffs in the suit claim that Gilead's actions caused the cost of the life-saving treatment to rise.
Gilead will donate its PrEP medication Truvada, which is used to reduce the risk of HIV infection and usually sells for $1,600 to $2,000 a month in the United States.
WASHINGTON (AP) — The Health and Human Services Department announced Thursday that California-Based Gilead Sciences Inc. has agreed to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year.
Gilead Sciences, Inc. (NASDAQ: GILD ), which recently suffered setbacks in non-alcoholic steatohepatitis drug development and is left to contend with a maturing HIV franchise, is looking elsewhere to develop ...
Is Gilead Sciences an Attractive Pick after Q1 Results?(Continued from Prior Part)Yescarta growth trendsIn the first quarter, Gilead Sciences’ (GILD) cell therapy product, Yescarta, reported revenues of $96 million, a sequential rise of 19%.